HSBC has moved AstraZeneca to a Hold rating from Buy and trimmed its target price to 13,750 pence from 16,500 pence after the pharmaceutical group reported that its Wainua Phase 3 study did not achieve the trial's primary endpoint.
The downgrade followed the bank's assessment that the Wainua outcome undermines the upside scenario it had previously held for the company. "Wainua setback impairs our bull case, given the more difficult catalyst path ahead," HSBC analyst Rajesh Kumar wrote in a note explaining the change in stance.
Market reaction was immediate. Shares of the British drugmaker fell 1.3% in London trading, while the company's U.S.-listed shares declined 1.5% in premarket trading.
Why HSBC changed its view
HSBC said earlier success in the CARDIO-TTR trial had supported its positive view on AstraZeneca, with that program representing a market opportunity it valued at more than $5 billion. But the bank set out three reasons for losing conviction in its prior bullish case.
- First, HSBC acknowledged that a route to more than $80 billion in peak revenues by 2030 remains possible, but now depends on a set of catalysts that are more unpredictable and are unlikely to report before 2027.
- Second, HSBC's own analysis of the company’s pipeline trials left it "rather uncomfortable" about the upcoming SERENA-4 and AVANZAR readouts, which the bank expects in the second half of 2026.
- Third, Kumar warned that "if three trials fail in a sequence, the widely held view of Astra’s market-leading R&D platform might lose its shine," a development that could limit the stock's ability to re-rate higher.
In closing his note, Kumar said: "We downgrade the stock to a Hold rating (from Buy) as we no longer find the risk-reward balance attractive, particularly with the remaining catalyst path for 2026 (SERENA-4, AVANZAR) skewed to downside risks."
HSBC scenario analysis and timing risks
HSBC ran scenario analysis to model potential outcomes. The bank observed that if downside scenarios unfold for SERENA-4 and AVANZAR, investor concern over AstraZeneca's ability to manage revenue declines around significant patent expiries in the early 2030s could constrain upside in the near term. HSBC said such a constrained upside would likely be "capped on a 6-9-month basis," meaning the stock's recovery would be dependent on successful catalysts emerging in 2027.
The bank's reassessment links immediate market moves with a forward-looking view of the company’s trial calendar and potential revenue pressures. The combination of a failed Phase 3 readout and an uncertain sequence of upcoming study results has prompted HSBC to dial back optimism until more positive clinical evidence appears.
Market and sector context
The downgrade and subsequent share weakness highlight near-term sensitivity in the pharmaceutical sector to clinical trial outcomes and timing of key readouts. For investors, the update underscores how trial results can rapidly alter the risk-reward calculus for large-cap drugmakers with concentrated clinical catalysts.